Tumor cell interactions with the extracellular matrix during invasion and metastasis.

Recent findings have produced great strides in developing an understanding of the molecular events involved in processes necessary for tumor cell invasion and subsequent metastasis formation. This information has been useful in developing new targets for therapeutic intervention such as disruption of tumor cell attachment by peptide analogues of cell adhesion molecules and the use of protease inhibitors to limit extracellular matrix proteolysis required for tumor cell invasion. Future efforts must focus on how the events of cell attachment, matrix proteolysis, and cell migration are controlled and integrated. This requires a better understanding of the transcriptional controls and cell signaling mechanisms that are involved in these events. Preliminary findings suggest that cell-matrix interactions influence gene expression and that the protease inhibitor balance can greatly influence cell-matrix interactions. Therefore it appears that all three steps in the invasive process are linked and interdependent. While this complicates the study of these processes, it is our belief that understanding this interdependence is critical for further development of metastasis research.

[1]  D. Miles,et al.  Activity of type IV collagenases in benign and malignant breast disease. , 1993, British Journal of Cancer.

[2]  S. Ménard,et al.  Prognostic significance of the 67-kilodalton laminin receptor expression in human breast carcinomas. , 1993, Journal of the National Cancer Institute.

[3]  T M Grogan,et al.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.

[4]  U. Moll,et al.  Mr 92,000 Type IV Collagenase Is Increased in Plasma of Patients with Colon Cancer and Breast Cancer , 1993 .

[5]  Y. Sasaguri,et al.  Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study. , 1993, American journal of clinical pathology.

[6]  Catherine,et al.  Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. , 1993, Cancer research.

[7]  P. Chambon,et al.  Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. , 1992, The Journal of investigative dermatology.

[8]  L. Liotta,et al.  Linkage analysis demonstrates that the Timp-2 locus is on mouse chromosome 11. , 1992, Genomics.

[9]  Kerbel Rs Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. , 1992 .

[10]  L. Liotta,et al.  Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. , 1992, The Journal of biological chemistry.

[11]  R Poulsom,et al.  Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. , 1992, The American journal of pathology.

[12]  C. Dinney,et al.  Metastatic model for human prostate cancer using orthotopic implantation in nude mice. , 1992, Journal of the National Cancer Institute.

[13]  L. Liotta,et al.  Evaluation of Basement Membrane Components and the 72 kDa Type IV Collagenase in Serous Tumors of the Ovary , 1992, The American journal of surgical pathology.

[14]  M. Cockett,et al.  The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. , 1992, The Biochemical journal.

[15]  M. Hendrix,et al.  Role of the alpha v beta 3 integrin in human melanoma cell invasion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Hurskainen,et al.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. , 1992, Cancer research.

[17]  W. Stetler-Stevenson,et al.  Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. , 1992, Biochemistry.

[18]  I. Hart,et al.  Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. , 1991, Cancer research.

[19]  L. Liotta,et al.  Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: Human melanoma and ras‐transfected NIH3T3 cells , 1991, International journal of cancer.

[20]  D. Powe,et al.  Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours , 1991, International journal of cancer.

[21]  E. Howard,et al.  Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. , 1991, The Journal of biological chemistry.

[22]  K. Suzuki,et al.  Substrate specificities and activation mechanisms of matrix metalloproteinases. , 1991, Biochemical Society transactions.

[23]  Kenneth M. Yamada,et al.  Adhesive recognition sequences. , 1991, The Journal of biological chemistry.

[24]  W. Fiers,et al.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role , 1991, Cell.

[25]  L. Liotta,et al.  Laminin receptors, collagenase IV and prognosis in node‐negative breast cancers , 1991, International journal of cancer.

[26]  L. Liotta,et al.  Tumor cell invasion inhibited by TIMP-2. , 1991, Journal of the National Cancer Institute.

[27]  H. Shimada,et al.  Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. , 1991, Cancer research.

[28]  J. Thiery,et al.  Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Birkedal‐Hansen,et al.  Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. , 1991, Biochemistry.

[30]  L. Matrisian,et al.  Expression and localization of the matrix metalloproteinase pump‐1 (MMP‐7) in human gastric and colon carcinomas , 1991, Molecular carcinogenesis.

[31]  T. Hamilton,et al.  Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel). , 1991, Invasion & metastasis.

[32]  H. Yamamoto,et al.  Motility factor produced by malignant glioma cells: role in tumor invasion. , 1990, Journal of neurosurgery.

[33]  A Yasui,et al.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. , 1990, European journal of biochemistry.

[34]  J Vandekerckhove,et al.  Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells , 1990, The Journal of cell biology.

[35]  L. Liotta,et al.  Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. , 1990, The Journal of biological chemistry.

[36]  L. Orci,et al.  Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene , 1990, Cell.

[37]  C. Meijer,et al.  Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). , 1990, Leukemia.

[38]  I. Stamenkovic,et al.  CD44 is the principal cell surface receptor for hyaluronate , 1990, Cell.

[39]  T. Wobbes,et al.  Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors , 1990, International journal of cancer.

[40]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[41]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[42]  R. Kerbel Growth dominance of the metastatic cancer cell: cellular and molecular aspects. , 1990, Advances in cancer research.

[43]  L. Liotta,et al.  The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. , 1989, The Journal of biological chemistry.

[44]  R. Tizard,et al.  Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes , 1989, Cell.

[45]  A. Eisen,et al.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[46]  W. Birchmeier,et al.  Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion , 1989, The Journal of cell biology.

[47]  P. Waterhouse,et al.  Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. , 1989, Science.

[48]  E. Kohn,et al.  Insulin-like growth factors stimulate chemotaxis in human melanoma cells. , 1988, Biochemical and biophysical research communications.

[49]  H. Willard,et al.  A primary genetic map of the pericentromeric region of the human X chromosome. , 1988, Genomics.

[50]  M. Humphries,et al.  Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. , 1988, The Journal of clinical investigation.

[51]  Brenda Kahan,et al.  Nerve growth factor stimulation of mouse embryonal carcinoma cell migration. , 1987, Cancer research.

[52]  L. Liotta,et al.  Role of laminin receptor in tumor cell migration. , 1987, Cancer research.

[53]  L. Liotta,et al.  Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains , 1987, The Journal of cell biology.

[54]  E Ruoslahti,et al.  New perspectives in cell adhesion: RGD and integrins. , 1987, Science.

[55]  E. Roos,et al.  Inhibition of lymphoma invasion and liver metastasis formation by pertussis toxin. , 1987, Cancer research.

[56]  L. Liotta,et al.  Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration , 1987, Nature.

[57]  G. Nicolson,et al.  Chemotactic response of rat mammary adenocarcinoma cell clones to tumor-derived cytokines. , 1987, Biochemical and biophysical research communications.

[58]  L. Liotta,et al.  Pertussis toxin inhibits stimulated motility independently of the adenylate cyclase pathway in human melanoma cells. , 1987, Biochemical and biophysical research communications.

[59]  L. Liotta,et al.  Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. , 1987, Cancer research.

[60]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[61]  L. Liotta,et al.  Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[62]  L. Liotta,et al.  Tumor cell autocrine motility factor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[63]  R. Thompson,et al.  Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Daynes,et al.  Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. , 1985, Journal of immunology.

[65]  H. Bourne,et al.  Pertussis toxin inhibition of chemotactic factor-induced calcium mobilization and function in human polymorphonuclear leukocytes , 1985, The Journal of experimental medicine.

[66]  H. Welgus,et al.  Human skin fibroblast collagenase inhibitor. Comparative studies in human connective tissues, serum, and amniotic fluid. , 1983, The Journal of biological chemistry.

[67]  J. Reynolds,et al.  Purification of rabbit bone inhibitor of collagenase. , 1981, The Biochemical journal.

[68]  D. R. Coman Mechanisms responsible for the origin and distribution of blood-borne tumor metastases: a review. , 1953, Cancer research.